ARCH Venture Management LLC Invests $129.35 Million in Vir Biotechnology, Inc. $VIR

ARCH Venture Management LLC bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,694,163 shares of the company's stock, valued at approximately $129,353,521. Vir Biotechnology makes up about 0.0% of ARCH Venture Management LLC's investment portfolio, making the stock its 6th largest holding. ARCH Venture Management LLC owned about 7.50% of Vir Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fiduciary Financial Advisors acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Vir Biotechnology by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company's stock valued at $41,000 after acquiring an additional 1,390 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Vir Biotechnology in the second quarter valued at about $35,000. UMB Bank n.a. raised its holdings in Vir Biotechnology by 1,418.7% during the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company's stock worth $43,000 after acquiring an additional 6,597 shares in the last quarter. Finally, CWM LLC raised its holdings in Vir Biotechnology by 23.0% during the fourth quarter. CWM LLC now owns 8,804 shares of the company's stock worth $53,000 after acquiring an additional 1,646 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VIR has been the topic of several recent analyst reports. Leerink Partners boosted their price target on Vir Biotechnology from $20.00 to $21.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 3rd. Morgan Stanley set a $25.00 price objective on Vir Biotechnology in a report on Thursday, August 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Wall Street Zen upgraded shares of Vir Biotechnology from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Vir Biotechnology in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $21.57.

Insider Activity

In other news, Director Janet Napolitano sold 3,200 shares of the company's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the transaction, the director owned 21,216 shares of the company's stock, valued at approximately $200,491.20. This represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by corporate insiders.

Vir Biotechnology Price Performance

Shares of VIR opened at $10.83 on Friday. The company's 50-day moving average is $9.59 and its 200-day moving average is $9.30. The firm has a market capitalization of $1.83 billion, a PE ratio of -5.82 and a beta of 1.66. Vir Biotechnology, Inc. has a fifty-two week low of $4.75 and a fifty-two week high of $11.66.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.33 by $0.14. The business had revenue of $238.95 million for the quarter, compared to analyst estimates of $135.88 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. Vir Biotechnology's quarterly revenue was up 19582.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.80) EPS. Analysts predict that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.